PATTERNS AND RISK FACTORS FOR NON-COMPLIANCE WITH HMG-COA INHIBITORS IN A MANAGED CARE POPULATION
CHOLESTEROL GOAL ATTAINMENT IN PATIENTS WITH DIABETES
INFLUENCE OF DIABETES AND BASELINE ST-SEGMENT CHANGE STATUS ON THE COST-EFFECTIVENESS OF AN EARLY INVASIVE VS. CONSERVATIVE STRATEGY FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
EFFECTIVENESS OF AMLODIPINE VS. VALSARTAN UPON BLOOD PRESSURE CHANGE AND CONTROL AMONG HYPERTENSIVE ADULTS
AN ECONOMETRIC APPROACH TO GENERATING POPULATION COST ESTIMATES FOR EVENT-TIME DATA
COMPARISON OF PATIENT SELF-REPORTED HEALTHCARE RESOURCE UTILIZATION TO ELECTRONIC RECORD DATA
THE IMPACT OF REQUIRING A FIXED PERIOD OF ELIGIBILITY IN ECONOMIC AND EPIDEMIOLOGICAL STUDIES THAT UTILIZE LONGITUDINAL DATA
AUTOMATING ECONOMIC ANALYSIS OF CO-MEDICATION USE IN CLINICAL TRIALS
QUALITY OF LIFE, UTILITY, AND WILLINGNESS TO PAY IN PATIENTS WITH DIABETES
CLINICAL IMPROVEMENT AND RESPONSIVENESS OF PHYSICAL FUNCTION MEASURES
DIABETIC PATIENTS' WILLINGNESS TO PAY FOR DIABETES EDUCATION BY PHARMACISTS
SMOKING STATUS AND HEALTH-RELATED QUALITY OF LIFE (HRQOL)
SUICIDE ATTEMPTS BY ADOLESCENTS
A RANDOMIZED CONTROLLED TRIAL OF A DRUG USE REVIEW INTERVENTION FOR ANTIBIOTICS MEDICATIONS FOR OTITIS MEDIA
RELIABILITY AND VALIDITY OF KINDL CHILDREN GENERIC HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE IN AN ASIAN SCHOOL-BASED SAMPLE
LONGITUDINAL EXAMINATION OF OUTCOMES ASSOCIATED WITH BOTULINUM TOXIN USE IN CHILDREN WITH CEREBRAL PALSY
THE COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM A STATE MEDICAID PROGRAM PERSPECTIVE
NONCONFORMANCE WITH NCEP-ATP III RECOMMENDATION ON LIPID/LIPOPROTEIN MEASUREMENT AT BASELINE
COST-EFFECTIVENESS OF CLOPIDOGREL IN PATIENTS WITH ISCHEMIC STROKE, MYOCARDIAL INFARCTION, OR PERIPHERAL ARTERIAL DISEASE
CURRENT PATTERNS OF CARE AND TREATMENT COSTS ASSOCIATED WITH VENOUS THROMBOEMBOLIC DISEASE
GENDER VARIATION IN QUALITY OF PHARMACOLOGIC CARE OF CHILDREN DIAGNOSED WITH ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (ADHD)
THE RELATIONSHIP OF ASTHMA AND GENERALIZED ANXIETY DISORDER IN ADULTS
EVALUATING THE ECONOMIC CONSEQUENCES OF EARLY SSRI DROP-OUTS IN DEPRESSION
DRUG UTILIZATION ANALYSIS OF THE SSRI CLASS IN A MEDICAID HMO
COST-EFFECTIVENESS OF TOPIRAMATE AS ADJUNCTIVE TREATMENT IN REFRACTORY EPILEPSY—A PROBABILISTIC ASSESSMENT OF TREATMENT STRATEGIES
AN ESTIMATE OF THE DIRECT COSTS OF MIGRAINE IN THE UNITED STATES USING THE MEDICAL EXPENDITURE PANEL SURVEY
ECONOMIC ANALYSIS OF ACUTE MIGRAINE THERAPY UTILIZATION WITHIN THE WISCONSIN STATE MEDICAID POPULATION
ARE ELDERLY PATIENTS RECEIVING APPROPRIATE ANTIEPILEPTIC DRUGS?
THE IMPACT OF AN ALLERGY MANAGEMENT PROGRAM ON LOST PRODUCTIVE TIME AT WORK
COST ANALYSIS OF HEPATITIS C VIRUS (HCV) INFECTION
WORK LOSS AND HEALTHCARE UTILIZATION AMONG U.S. EMPLOYEES WITH CHRONIC NON-CANCER PAIN
ALLERGY PREVALENCE, COST, AND PRODUCTIVITY LOSS IN AN INSURED EMPLOYEE POPULATION
NON-PROCUREMENT OF PRESCRIPTION MEDICATIONS DUE TO COST IN MEDICARE BENEFICIARIES
MEDICATION TREATMENT PERSISTENCE OF OVERACTIVE BLADDER/URINARY INCONTINENCE PATIENTS IN A CALIFORNIA MEDICAID PROGRAM AND THE BENEFIT OF THEIR REFILL ADHERENCE ON URINARY TRACK INFECTION
PREDICTIVE MODEL OF MEDICATION ADHERENCE IN CARDIOVASCULAR DISEASE
A TIME-VARYING SURVIVAL MODEL FOR THE ASSOCIATION OF ADHERENCE WITH HMGCOA INHIBITORS TO THE RISK OF ADVERSE EVENTS
RELATIONSHIP BETWEEN DIRECT-TO-CONSUMER ADVERTISING AND PRODUCT INNOVATIVENESS
ECONOMIC IMPACT OF PROZAC® PATENT EXPIRATION AND THE 180-DAY GENERIC FLUOXETINE EXCLUSIVITY IN A PUBLICLY-FINANCED PRESCRIPTION PROGRAM
PHYSICIAN ATTITUDE TOWARD ACADEMIC DETAILING AND OTHER DRUG COST-CONTAINMENT STRATEGIES IN A STATE HEALTH INSURANCE PROGRAM
ARE SICK PEOPLE LESS RESPONSIVE TO PRESCRIPTION BENEFIT CHANGES?
IMPACT OF PARTICIPANT COST-SHARE ON COMPLIANCE RATES IN PARTICIPANTS WITH DIABETES
INCOME DISPARITY IN DIFFUSION OF ORAL DIABETES THERAPY 1999–2001
ORAL ANTIHYPERGLYCEMIC MEDICATION NON-ADHERENCE AND SUBSEQUENT HOSPITALIZATION AMONG PERSONS WITH TYPE 2 DIABETES
MULTI-SITE EVALUATION OF DIABETES DISEASE MANAGEMENT PROGRAMS USING THE DIABETES MANAGEMENT EVALUATION TOOL (DMET)
CHANGES IN FUNCTIONAL DISABILITY LEVELS AND MEDICAL EXPENDITURES AMONG ELDERLY PERSONS
RELATIONSHIP BETWEEN QUALITY OF LIFE AND COGNITIVE STATUS AMONG LONG-TERM CARE FACILITY RESIDENTS IN WEST VIRGINIA
A COMPARATIVE COST ANALYSIS OF ALZHEIMER'S DISEASE VERSUS VASCULAR DEMENTIA
INAPPROPRIATE DRUG PRESCRIBING IN OUTPATIENT CARE FOR THE ELDERLY
COMPLIANCE WITH DRUG TREATMENT IN SWEDEN
THE ASSOCIATION OF PRACTICE GUIDELINES AND OTHER FACTORS WITH HOSPITAL LENGTH OF STAY (LOS) AND MORTALITY IN PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP), HEART FAILURE (HF) AND SEDATED INTENSIVE CARE PATIENTS
THE EFFECT OF HOSPITAL COMPLIANCE WITH THE JOINT COMMISSION ON THE ACCREDITATION OF HEALTHCARE ORGANIZATIONS (JCAHO) PERFORMANCE MEASURES AND PUBLISHED GUIDELINES ON OUTCOMES OF PATIENTS WITH HEART FAILURE
BIAS IN CATEGORICAL MEDICATION COMPLIANCE ASSESSMENT
CORRELATIONS BETWEEN A STAGE OF CHANGE MEASURE AND FOUR VALIDATED MEASURES OF MEDICATION COMPLIANCE
THE INFLUENCE OF SELF-EFFICACY AND COMPLIANCE IN HYPERTENSION PATIENTS, DIABETES PATIENTS,AND UPPER RESPIRATORY TRACT INFECTIOUS PATIENTS WHO NEED SHORT COURSE ANTIBIOTICS AT FORT ADISORN HOSPITAL,THAILAND 2000
CRITICAL EVALUATION OF INTERVENTIONS TO ENHANCE PATIENT COMPLIANCE WITH CHRONIC MEDICATIONS
DIFFERENTIAL ECONOMIC IMPACT OF VARIABLE COMPLIANCE AND VARIABLE PERSISTENCE WITH PRESCRIBED, LONG-TERM DRUG REGIMENS
FEASIBILITY OF HEALTH AND WELLNESS PROGRAMS VIA AN EMPLOYER-BASED INTRANET SITE
IMPACT OF RISK DISCLOSURES IN DIRECT-TO-CONSUMER ADVERTISING ON ELDERLY CONSUMERS' BEHAVIORAL INTENT
A STUDY ON SAVINGS AND HEALTH-RELATED SAVING MOTIVE IN CHINESE RESIDENTS IN HONG KONG
ATTITUDES AS OUTCOMES
IMPROVING THE USE OF MEDICINES AND THE HEALTH KNOWLEDGE OF CONSUMERS THROUGH CIVIL EDUCATION SYSTEMS
DEALIING WITH PRESCRIPTION DRUGS
PUBLIC SUBSIDY OF PHARMACEUTICALS
POLISH GUIDELINES FOR COSTING IN PHARMACOECONOMIC EVALUATION IN COMPARISON TO EXISTING GUIDANCE FOR COSTING IN OTHER COUNTRIES
SOURCES OF VARIATION IN DRUG COSTS AMONG STATE MEDICAID PROGRAMS
INCREASED HEALTHCARE UTILIZATION FOR THE ELDERLY DUE TO INAPPROPRIATE PRESCRIPTION USE
PRESCRIPTION DRUG UTILIZATION PATTERNS AND CHARACTERISTICS OF RETAIL AND MAIL ORDER PHARMACY UTILIZERS
DOCUMENTING THE RESULTS OF CLINICAL INTERVENTIONS BY PHARMACISTS IN AN AMBULATORY SETTING
PHARMACISTS' UTILIZATION AND PERCEPTIONS OF DRUG INTERACTION PROGRAM WARNINGS
REVIEWS OF UTAH MEDICAID HIGH UTILIZERS TO CONTROL DRUG COSTS
PRESCRIBING INCENTIVE SCHEMES
GENERIC COMPETITION IN THE PHARMACEUTICAL INDUSTRY
DOES THE PAST PREDICT THE FUTURE?
INAPPROPRIATE PRESCRIPTION DRUG USE AND REDUCED HEALTH STATUS FOR THE ELDERLY
HEALTH RELATED QUALITY OF LIFE AMONG PRESCRIPTION DRUG USERS IN SWEDEN
HEALTH INVOLVEMENT
PREDICTIVE FACTORS OF INPATIENT DRUG COSTS IN A MOTHER-CHILD TEACHING HOSPITAL
RATES OF CONTINUATION OF NON FORMULARY MEDICATIONS FOR CHRONIC DISEASE SUFFERERS IN MULTI-TIERED PHARMACY BENEFIT PLANS
WHAT WE HAVE MISUNDERSTOOD OF THE HIGH RATE OF OUT-OF-POCKET PAYMENTS IN HEALTH CARE SYSTEMS
A COMPARISON OF HEALTH CARE REIMBURSEMENT STRATEGIES
RISK SHARING IN A STATE FUNDED HEALTH SERVICE
IMPROVING OUTCOMES THROUGH ACCESS TO CRITIQUED ECONOMIC EVALUATIONS
AN ANALYSIS OF THE HEALTH AND PRODUCTIVITY COST BURDEN OF THE PHYSICAL AND MENTAL HEALTH CONDITIONS AFFECTING SIX LARGE CORPORATIONS IN 1999
COSTS ASSOCIATED WITH FALLS IN COMMUNITY DWELLING ELDERS
UTILIZATION PATTERNS AND RISK FACTORS FOR HIGH COST RECIPIENTS IN MEDICAID POPULATION
THREE-YEAR PREDICTIVE MODEL OF MEDICAL COST RISK AND METHODOLOGICAL ISSUES RELATED TO AN EXPANDED PHARMACY CLAIMS RISK INDEX
DOES POOR HEALTH STATUS LEAD TO LOWER INCOME PRODUCTIVITY?
WORK IMPAIRMENT DUE TO CHRONIC DISEASE IN A POPULATION OF WISCONSIN SCHOOLTEACHERS
PHARMACY REIMBURSEMENT FOR PHARMACEUTICAL CARE SERVICES IN AMBULATORY CARE SETTINGS AT US SCHOOLS OF PHARMACY
EVALUATION OF AN INTEGRATED WORKERS' COMPENSATION/HEALTH INSURANCE PHARMACY BENEFIT PROGRAM
WITHDRAWN
ROLES OF DIFFERENT TYPES OF HEALTH INSURANCE ON ACCESS AND UTILIZATION
DOES REDUCING LENGTH OF POSTOPERATIVE STAY REDUCE CANCELLATION OF OPERATIONS?
CHARACTERISTICS AND RISK FACTORS FOR HOSPITAL READMISSION IN MEDICAID POPULATION
PHYSICIAN HABIT AS A DETERMINANT OF MEDICATION CHOICE
HOSPITAL PERFORMANCE EVALUATION METHODS IN A REGIONAL MANAGED CARE ORGANIZATION
HOSPITALIZATIONS RELATED TO DOMESTIC VIOLENCE
DOMESTIC VIOLENCE
MEDICAL DEVICE PROBLEMS IN INTENSIVE CARE UNITS
VARIATIONS IN UTILIZATION RATES, CLINICAL TRIGGERS AND OUTCOMES OF X-RAYS IN A DEVELOPING COUNTRY
MORBIDITY, COMORBIDITY, PHYSICIAN COSTS AND RACE DIFFERENCES IN MORTALITY AMONG THE MEDICARE ELDERLY
EQUITY OF ACCESS TO HEALTH CARE SERVICES
ASSOCIATION BETWEEN INCOME AND HEALTH STATUS IN THE ELDERLY CHINESE IN HONG KONG
DIRECT OBSERVATION IN INTENSIVE CARE UNITS
USE OF ALTERNATIVE THERAPY, QUALITY OF LIFE,AND HEALTHCARE SPENDING IN CHINESE PATIENTS WITH OSTEOARTHRITIS
EFFECTS OF A PRIOR AUTHORIZATION POLICY FOR CYCLOOXYGENASE-2 INHIBITORS ON HEALTH-RELATED OUTCOMES IN A MANAGED CARE MEDICAID POPULATION
IMPACT OF THE INTRODUCTION OF THE COX2 INHIBITORS ON THE ANALGESIC MARKET IN A PUBLIC EMPLOYEES INDEMNITY INSURANCE PROGRAM
ECONOMIC IMPLICATIONS OF NONCOMPLIANCE WITH OSTEOPOROSIS TREATMENT IN ACTUAL PRACTICE
WITHDRAWN
ECONOMIC ANALYSIS OF NOVEL DISEASEMODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) FOR RHEUMATOID ARTHRITIS (RA) PATIENTS IN A MANAGED CARE SETTING
ASSESSMENT OF THE BURDEN OF RHEUMATOID ARTHRITIS IN FRENCH HOSPITALS
COST BURDEN OF HIP AND KNEE REPLACEMENTS IN OHIO AND IN THE UNITED STATES
THE IMPLICATIONS OF RHEUMATOID ARTHRITIS IN THE UK SECONDARY CARE HEALTH CARE SYSTEM
A COST ANALYSIS OF CELECOXIB VERSUS DICLOFENAC PLUS OMEPRAZOLE FOR THE TREATMENT OF ARTHRITIS IN A GROUP OF HIGH-RISK CHINESE PATIENTS
VERIFICATION OF A DECISION ANALYTIC MODEL ASSUMPTION USING REAL WORLD PRACTICE DATA
COST-EFFECTIVENESS OF RALOXIFENE FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES IN AUSTRALIA
COMPLIANCE WITH DRUG THERAPIES FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS
RETROSPECTIVE ANALYSIS OF THE IMPACT OF MEDICATION NONADHERENCE ON CLINICAL OUTCOMES AND COSTS IN PATIENTS WITH OSTEOPOROSIS RECEIVING ALENDRONATE USING AN INTEGRATED PAYOR DATABASE
INITIAL VALIDATION OF THE WILLINGNESS TO PAY (WTP) TECHNIQUE FOR MEASURING HEALTH CARE PREFERENCES IN JUVENILE IDIOPATHIC ARTHRITIS (JIA)
GASTROINTESTINAL (GI) SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE (HRQL) IN JUVENILE IDIOPATHIC ARTHRITIS (JIA)
COMPARING SHORT FORM AND RAND PHYSICAL AND MENTAL HEALTH SUMMARY SCORES
PREVALENCE OF DEPRESSIVE SYMPTOMATOLOGY AND ITS RELATIONSHIP TO HRQOL IN ARTHRITIS
A UTILITY VALUATION STUDY ASSESSING TREATMENT OUTCOMES IN OSTEOARTHRITIS
SECOND TREATMENT PATTERNS IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE
DARBEPOETIN ALFA 200 MCG EVERY 2 WEEKS (Q2W) AND EPOETIN ALFA 40,000 UNITS EVERY WEEK (QW) IN CHEMOTHERAPY-INDUCED ANEMIA PATIENTS RESULT IN SIMILAR INITIAL HEMOGLOBIN OUTCOMES
PERFORMANCE OF THE MC-PEEK-SCORE FOR SURGICAL OUTCOME
ESTIMATING LIFE LOST DUE TO CANCER IN THE US—A COMPARISON OF LONGITUDINAL AND CROSS-SECTIONAL MEASURES
HEALTHCARE EXPENDITURES ASSOCIATED WITH SEVEN TUMOR TYPES OF INTEREST (TOI) USING LARGE EMPLOYERS' CLAIMS DATABASE
DOSE CONVERSION OF ERYTHROPOIETIC AGENTS IN CHEMOTHERAPY-INDUCED ANEMIA
CERVICAL CANCER SCREENING IN THE PHILIPPINE SETTING
PREVALENCE RATES AND COST OF DEPRESSION AMONG PROSTATE CANCER PATIENTS
PATIENT CHARACTERISTICS IMPACTING LENGTH OF STAY AND IN-PATIENT CHARGES AMONG US COLORECTAL CANCER PATIENTS
FIVE-YEAR, DIRECT, MEDICAL COSTS AMONG VETERANS ADMINISTRATION PATIENTS WITH CANCER OF THE SIGMOID COLON
ESTIMATING THE BUDGET AND HEALTH IMPACTS OF LETROZOLE FOR ADVANCED BREAST CANCER
ECONOMIC BURDEN OF ACTINIC KERATOSIS AND SQUAMOUS CELL CARCINOMA IN AMBULATORY CARE
PHARMACOECONOMICAL ANALYSIS OF UNFRACTIONATED HEPARIN VERSUS DALTEPARIN IN PATIENTS WITH MALIGNANCIES
MEDICAL TREATMENT FOR CHRONIC MYELOID LEUKAEMIA (CML)
AGREEMENT OF HEALTH UTILITIES INDEX SCORES AMONG SURVIVORS OF CANCER IN CHILDHOOD,THEIR PARENTS AND THEIR DOCTORS IN URUGUAY
SPECIFIC CHOICES AND EXPENDITURES FOR HERBAL MEDICINES BY CANCER PATIENTS
A WEIGHTED INDEX FORM OF THE FACT-L FOR USE IN ECONOMIC EVALUATION
ASSESSMENT OF PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH PROSTATE CANCER
QUALITY OF LIFE PROFILE OF MEN AT-RISK FOR PROSTATE CANCER
FEAR OF CANCER RECURRENCE AFTER TREATMENT FOR PROSTATE CANCER
DIFFERENCES IN HUSBAND/WIFE PREFERENCES AND UTILITIES FOR PROSTATE CANCER THERAPIES
DEVELOPING A MEASUREMENT STRATEGY FOR PATIENT-REPORTED OUTCOMES
HEALTH-RELATED QUALITY OF LIFE BURDEN OF HEAD AND NECK CANCER
DEVELOPMENT OF A PREFERENCE ELICITATION INSTRUMENT FOR USE IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES IN A PROSPECTIVE RANDOMIZED CLINICAL TRIAL
FACTORS INFLUENCING A POTENTIALLY INAPPROPRIATE DERMATOLOGICAL MEDICATION COMBINATION PRESCRIPTION AMONG U.S. OUTPATIENT PHYSICIANS
COST-EFFECTIVENESS OF BIMATOPROST VERSUS LATANOPROST PLUS ADJUNCTIVE PRODUCTS FOR GLAUCOMA TREATMENT
A MODEL-BASED PHARMACOECONOMIC ANALYSIS OF BRIMONIDINE TARTATE 0.2% AS AN ADJUNCTIVE THERAPY TO BETA-BLOCKERS IN THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION IN ADULT PATIENTS IN NORWAY
COST-EFFECTIVENESS OF BIMATOPROST 0.03% VERSUS A COMBINATION PRODUCT OF TIMOLOL 0.5% AND DORZOLAMIDE 2.0% FOR GLAUCOMA
MODEL-BASED COMPARATIVE PHARMACOECONOMIC ANALYSES OF BIMATOPROST 0.03% IN THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION IN ADULT PATIENTS IN AUSTRIA AND FINLAND
ECONOMIC EVALUATION OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR SMALL SUBFOVEAL CNV LESIONS
COST-EFFECTIVENESS ANALYSIS OF CATARACT CONTROL IN 14 WORLD REGIONS
BURDEN OF ILLNESS OF ECZEMA IN CANADA
A BASELINE ASSESSMENT OF THE VALIDITY OF THE 39-ITEM NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE IN GERMAN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
PATIENT REPORTED OUTCOMES AND ECONOMIC IMPLICATIONS OF A REFORMULATION TO IMPROVE BRIMONIDINE 0.2%
QUALITY OF LIFE IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION—A CONJOINT ANALYSIS APPROACH
AN APPRAISAL OF VISION-RELATED QUALITY OF LIFE INSTRUMENTS
COMPARING THE QUALITY OF LIFE EFFECTS OF PRIMARY FOCAL HYPERHIDROSIS TO OTHER DERMATOLOGICAL CONDITIONS AS ASSESSED BY THE DERMATOLOGY LIFE QUALITY INDEX (DLQI)
IMPACT OF HYDROTHERAPY CARE ON THE QUALITY OF LIFE OF CHILDREN
THE FRENCH VERSION OF THE CARDIFF ACNE DISABILITY INDEX
PSORIASIS AND ATOPIC DERMATITIS
IMPACT OF HYDROTHERAPY CARES ON THE QUALITY OF LIFE OF PATIENTS' SUFFERING FROM SKIN DISEASES
PSORIASIS AND QUALITY OF LIFE
DEVELOPMENT AND VALIDATION OF A HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR WOMEN WITH MELASMA
IMPACT OF RISK MODELING INFORMATION ON THE PRESCRIBING OF COX-2 INHIBITOR AGENTS
ASSESSMENT OF THE UTILITY OF SALSALATE WITHIN A COX-2 INHIBITOR CLINICAL USAGE PROTOCOL
LOW DOSE ESOMEPRAZOLE (20MG) USE IN GENERAL PRACTICE
EFFECT OF COMPETITION ON ANTIULCER-GASTRIC-MEDICATION ACQUISITION COSTS FOR THE MEDICAID PROGRAM
ECONOMIC ASSESSMENT OF DRUGS AND GI HOSPITALIZATIONS ASSOCIATED WITH APPLYING VA CRITERIA FOR PRESCRIBING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS
THE COST-EFFECTIVENESS OF ALTERNATIVE STRATEGIES IN THE MANAGEMENT OF PATIENTS WITH UNINVESTIGATED DYSPEPSIA (UD)
COST-EFFECTIVENESS ANALYSIS OF ENDOSCOPIC SCLEROTHERAPY VERSUS LIGATION FOR THE PREVENTION OF REBLEEDING IN CHILDREN WITH OESOPHAGEAL VARICES
UTILIZATION IMPACT OF PROTON PUMP INHIBITOR ON TREATMET COSTS FOR GASTROESOPHAGEAL REFLUX DISEASE USING HEALTH CARE CLAIMS DATA IN TAIWAN
THE COST-EFFECTIVENESS OF HIGH DOSE ORAL VERSUS INTRAVENOUS PROTON PUMP INHIBITION IN HIGH-RISK PATIENTS WITH BLEEDING PEPTIC ULCERS HAVING UNDERGONE THERAPEUTIC ENDOSCOPY
TREATMENT PATTERNS AND HEALTH CARE COSTS OF MEBEVERINE-TREATED IBS PATIENTS
INCIDENCE AND COST OF LAPAROSCOPIC CHOLECYSTECTOMY IN THE US MANAGED CARE POPULATION
COST-MINIMIZATION ANALYSIS OF A PHARMACIST-DIRECTED, PANTOPRAZOLE INTRAVENOUS TO ORAL DOSAGE FORM CONVERSION PROGRAM
DIFFERENCES BETWEN ELDERLY AND YOUNGER ADULTS IN THE EPIDEMIOLOGY AND TREATMENT OF SYMPTOMATIC GERD AND NOCTURNAL GERD
GASTROESOPHAGEAL REFLUX IN INFANTS
ASSOCIATION BETWEEN SKIN TATTOOS AND HEPATITIS B OF 1/2000 PRIVATES AT ADISORN FORT HOSPITAL, THAILAND
TELITHROMYCIN (TEL) RESULTS IN FEWER HOSPITALIZATIONS THAN AMOXICILLIN-CLAVULANATE (AMC) IN THE OUTPATIENT TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB)
EFFECTIVENESS OF HAART IN REDUCING VIRAL LOAD (VL) AMONG A LARGE COHORT OF HIV-INFECTED PATIENTS—A SIGNIFICANT UNMET NEED
THE INFLUENCE OF PRESCRIPTION DRUG COVERAGE ON ANTIBIOTIC UTILIZATION IN ACUTE RESPIRATORY TRACT INFECTIONS
RELATIONSHIP BETWEEN PRESCRIPTION USE AND ANTIMICROBIAL RESISTANCE IN THE COMMUNITY
IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC RESISTANCE
IMPACT OF THE GRIER CONSENT DECREE ON ANTIBIOTIC COSTS FOR TENNCARE'S MANAGED MEDICAID PROGRAM
PATTERNS OF ANTIBIOTIC PRESCRIBING IN TREATING COMMUNITY-ACQUIRED PNEUMONIA OUTPATIENTS
IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC USE AND EXPENDITURES
THE ALLOCATION OF HIV PREVENTION FUNDS
DYSLIPIDEMIA MANAGEMENT AMONG HIV INFECTED PATIENTS TREATED WITH PROTEASE INHIBITORS (PI)
IMPLICATIONS OF APPLYING DIFFERENT NATIONAL GUIDELINES ADDRESSING SURGICAL ANTIBIOTIC PROPHYLAXIS
CHANGES IN ANTIRETROVIRAL (ARV) REGIMENS IN CLINICAL PRACTICE
POLICY EVALUATION FOR INFLUENZA VACCINATION OF ELDERLY IN JAPAN
ESTIMATING USAGE OF SELECTED ANTI-INFECTIVE DRUGS IN U.S. HOSPITALS
ASSESSMENT OF ECONOMIC MODELS OF ANTIRETROVIRAL THERAPIES IN HIV/AIDS
THE VALUE OF VACCINATING INFANTS AND CHILDREN WITH PNEUMOCOCCAL CONJUGATE VACCINE
INFLUENZA VACCINATION IN A MALAYSIAN COMPANY
ROUTINE CHILDHOOD VACCINATION AGAINST INFLUENZA
COST-CONSEQUENCES OF INFLUENZA VACCINATION FOR SCHOOL-AGED CHILDREN IN JAPAN
COST-EFFECTIVENESS OF SELECTED INTERVENTIONS TO REDUCE THE BURDEN OF CHILDHOOD PNEUMONIA AND DIARRHEA
TELITHROMYCIN (TEL) IS AN EFFECTIVE THERAPY FOR ADULT OUTPATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) AND IS ASSOCIATED WITH LOWER OVERALL HEALTHCARE COSTS THAN CLARITHROMYCIN (CLA)
ECONOMIC IMPACT OF ANTIBIOTIC RESISTANCE IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
COST EFFECTIVENESS ANALYSIS OF LINEZOLID VS. TEICOPLANIN FOR THE TREATMENT OF SERIOUS GRAM-POSITIVE BACTERIAL INFECTIONS IN A MULTINATIONAL RANDOMIZED TRIAL
A COST-EFFECTIVENESS ANALYSIS OF BACTERIAL ENDOCARDITIS PROPHYLAXIS FOR FEBRILE CHILDREN WITH CARDIAC LESIONS
LIFETIME GOVERNMENTAL COSTS OF SEVERE SEQUELAE OF PNEUMOCOCCAL MENINGITIS IN A WELFARE STATE
COST-EFFECTIVENESS OF CEFEPIME VERSUS CEFOTAXIME WHEN ADDED TO METRONIDAZOLE IN COMPLICATED INTRAABDOMINAL INFECTIONS
ESTIMATED COST SAVINGS OF DISCONTINUING SECONDARY PROPHYLAXIS FOR OPPORTUNISTIC INFECTIONS AFTER IMMUNOLOGICAL RECONSTITUTION WITH HAART
PHARMACOECONOMIC EVALUATION OF ANTIMICROBIAL AGENTS IN THE TREATMENT OF SEXUALLY TRANSMITTED DISEASES IN LAGOS UNIVERSITY TEACHING HOSPITAL
HOSPITALIZATION EXPENDITURE OF STREPTOCOCCUS PYOGENES-ASSOCIATED CELLULITIS IN THE UNITED STATES
THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C (CHC)
COST-EFFECTIVENESS ANALYSIS OF ANTI-VIRAL THERAPIES FOR CHRONIC HEPATITIS B IN TAIWAN
MEDICAL RESOURCE USE AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN BRAZIL
DIRECT MEDICAL COSTS ASSOCIATED WITH HEPATITIS B VIRUS (HBV) INFECTION IN THE UNITED STATES
ESTIMATING FUTURE HEPATITIS B VIRUS (HBV) DISEASE BURDEN IN THE UNITED STATES USING A DISEASE SIMULATION MODEL
COST-SAVINGS OF AN IV TO PO ACYCLOVIR SWITCH IN A STANDARDIZED HSV PROPHYLAXIS PROTOCOL ON A BMT UNIT
DOES EFFECTIVE POSTHERPETIC NEURALGIA THERAPY DECREASE THE COST-EFFECTIVENESS OF ANTIVIRALS FOR ZOSTER?
COST-EFFECTIVENESS OF LOPINAVIR/RITONAVIR COMPARED TO NELFINAVIR AS FIRST-LINE ANTIRETROVIRAL THERAPY IN TREATMENT-NAïve HIV PATIENTS
IMPACT OF METABOLIC ABNORMALITIES (HYPERTENSION, DIABETES MELLITUS, HYPERLIPIDEMIA) ON RESOURCE CONSUMPTION AND HEALTH CARE COSTS IN HIV-INFECTED PATIENTS
THE COST EFFECTIVENESS OF IMPROVED ADHERENCE TO ANTIRETROVIRAL TREATMENT
PERTUSSIS VACCINATION IN ADOLESCENTS
COST OF VARICELLA IN POLAND
THE EFFECT OF HEALTH PERCEPTION IN MODIFYING TOTAL HEALTH CARE EXPENDITURES WITHIN AN IMMUNIZED ELDERLY UNITED STATES POPULATION
THE COST OF SEVERE SEPSIS AT A TERTIARY CARE TEACHING INSTITUTION
THE COST EFFECTIVENESS OF PI BASED THERAPY WITH NELFINIVIR (NLF) COMPARED TO RITONAVIR (RTV) FOR PATIENTS WITH HIV/AIDS
HIV/AIDS PATIENTS
SIDE EFFECTS AND THEIR BURDEN ON HIV-INFECTED PATIENTS
ASSESSING PARENTS' PREFERENCE FOR A UNIQUE ANTIBIOTIC DOSE IN THE TREATMENT OF ACUTE OTITIS MEDIA IN CHILDREN BY USING A WILLINGNESS TO PAY METHOD
HOW DOES PATIENT REPORT OF SYMPTOM IMPACT RELATE TO CLINICAL FUNCTIONING IN CHRONIC BRONCHITIS?
VALIDATION OF THE HEALTH RELATED PRODUCTIVITY QUESTIONNAIRE DIARY (HRPQ-D) ON A SAMPLE OF PATIENTS WITH INFECTIOUS MONONUCLEOSIS
ASSESSING DISEASE-SPECIFIC UTILITY IN RECURRENT GENITAL HERPES (RGH)
GALANTAMINE REDUCES CAREGIVER TIME
IMPACT OF RIVASTIGMINE ON TIME TO FIRST ANTIPSYCHOTIC DRUG USE IN PATIENTS WITH ALZHEIMER'S DISEASE
USE OF WHO'S ICIDH-2 CLASSIFICATION SYSTEM IN A FUNCTIONAL ASSESSMENT OF MIGRAINEURS
PHYSICIAN PERCEPTIONS ON THE USE OF MEDICATIONS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER
COMPARISON OF USING NDC OR ICD CODES TO SELECT PAIN PATIENTS USING DATABASE ANALYSES
THE USE OF DISEASE-ALTERING NEW DRUGS FOR MULTIPLE SCLEROSIS TREATMENT
COMPLIANCE WITH THREE-TIMES DAILY METHYLPHENIDATE IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
A MARKOV MODEL OF TREATMENT OF NEWLY DIAGNOSED EPILEPSY IN THE UK—AN ASSESSMENT OF COST-EFFECTIVENESS OF TOPIRAMATE
COST-EFFECTIVENESS ANALYSIS OF PRAMIPEXOLE IN EARLY PARKINSON'S DISEASE
COST-EFFECTIVENESS OF ATOMOXETINE IN THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND ADOLESCENTS
MEDICAL CARE COSTS FOR TREATING ATTENTION DEFICIT/HYPERACTIVITY DISORDER—AN EMPIRICAL STUDY BASED ON A LARGE ADMINISTRATIVE CLAIM DATA
A COST CONSEQUENCE ANALYSIS OF THE MANAGEMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN THE UK
CAREGIVER HEALTH BENEFITS AND ASSOCIATED REDUCTIONS IN HEALTHCARE COSTS AS A CONSEQUENCE OF TREATING PATIENTS WITH DONEPEZIL
COST OF MULTIPLE SCLEROSIS BY LEVEL OF DISABILITY
COST-UTILITY ANALYSIS OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH GLATIRAMER ACETATE OR INTERFERON BETA IN SPAIN
THE COMPARISON OF DIFFERENT METHODS FOR DETERMINING THE IMPACT OF MIGRAINE PROPHYLAXIS ON COSTS
THE ECONOMIC BURDEN OF MIGRAINE AND COMORBID MENTAL CONDITIONS
ECONOMIC COMPARISON OF FIVE TRIPTAN STRATEGIES FOR MIGRAINE HEADACHES USING MONTE CARLO SIMULATION
COST PER SUCCESSFULLY TREATED PATIENT AS MEASURE OF EFFECTIVENESS IN COMPARING ELETRIPTAN TO SUMATRIPTAN
COST UTILITY ANALYSIS OF IMMUNOGLOBULINS (IVIG) VERSUS PLASMA EXCHANGE (PE) FOR THE TREATMENT OF GUILLAIN BARRE SYNDROME (GBS)
UTILIZATION CHARACTERISTICS OF NARCOTIC ANALGESICS IN WV WORKERS' COMPENSATION CLAIMANTS
PREVALENCE AND MEDICAL CARE COSTS OF BACK PAIN
COST-EFFECTIVENESS OF DRUG THERAPY FOR POSTHERPETIC NEURALGIA
ESTIMATES AND PATTERNS OF HEALTHCARE EXPENDITURES AMONG INDIVIDUALS WITH BACK PAIN IN THE US
DONEPEZIL VERSUS RIVASTIGMINE UTILIZATION PATTERNS IN A RETROSPECTIVE CLAIMS ANALYSIS
VALIDATING THE FACTOR STRUCTURE OF THE DISQ-24 USING STRUCTURAL EQUATION MODELING
ASSESSING BEHAVIORAL FUNCTIONING IN ALZHEIMER'S DISEASE
STUDY OF THE QUALITY OF LIFE IN PARKINSON'S DISEASE PATIENTS IN RUSSIA
CLINITRAC
CHANGES IN QUALITY OF LIFE RESULTING FROM TREATMENT FOR PERSONS WITH ADVANCED PARKINSON'S DISEASE
PARENT PERCEPTIONS OF MEDICATIONS FOR ADHD
QUALITY OF LIFE (QOL) IN PATIENTS WITH PARTIAL EPILEPSY IN MOSCOW
HOW DOES AN 11-POINT PAIN SCALE RELATE TO PREFERENCE ESTIMATES IN PATIENTS WITH CHRONIC PAIN AND CAN IT BE USED TO PREDICT PREFERENCES?
PATIENT PREFERENCE-BASED TREATMENT RECOMMENDATIONS FOR ENDOMETRIOSIS PAIN
AGE AND GENDER-STRATIFIED DIFFERENCES IN QUALITY OF LIFE IN ELDERLY CHRONIC PAIN PATIENTS
COMPARISON OF DIRECT HEALTH-CARE COST, HOSPITAL UTILIZATION AND MEDICATION PERSISTENCE BETWEEN EXTENDED RELEASE FORMS (ER) OF TOLTERODINE AND OXYBUTYNIN IN OVERACTIVE BLADDER/URINARY INCONTINENCE PATIENTS
FACTORS ASSOCIATED WITH DIALYSIS TREATMENT COSTS AMONG MEDICARE ENROLEES
US MEDICAL VISITS WITH DIAGNOSES PATHOGNOMONIC OF OVERACTIVE BLADDER
COST ANALYSIS OF NON-DIALYSIS RENAL INSUFFICIENCY (NDRI)
ANALYSIS OF COMORBIDITY, HOSPITAL UTILIZATION AND COST OF OVERACTIVE BLADDER IN A CALIFORNIA MEDICAID PROGRAM—A CASE-CONTROL STUDY
A RETROSPECTIVE CLAIMS ANALYSIS OF THE DIRECT COSTS OF STRESS URINARY INCONTINENCE
COMPARISON OF TACROLIMUS WITH CYCLOSPORIN IN KIDNEY TRANSPLANTATION
COSTS AND CLINICAL CONSEQUENCES OF ALFUZOSIN AND DOXAZOZIN IN BENIGN PROSTATIC HYPERPLASIA IN UKRAINE
COST-EFFECTIVENESS OF TAMSULOSIN, DOXAZOSIN AND TERAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
COST-MINIMISATION ANALYSIS AND ACCEPTANCE OF SELF-INJECTING SUBCUTANEOUSLY R-HUEPO WITH RECO-PEN® FOR MANAGEMENT OF ANAEMIA IN A POPULATION OF FRENCH ADULT PATIENTS ON DIALYSIS
THE ECONOMICS OF PHOSPHATE BINDERS IN RENAL DIALYSIS
COMPARING SENSITIVITY TO CHANGE BETWEEN I-QOL AND SF-36 IN A POPULATION WITH URINARY INCONTINENCE
DEVELOPMENT OF A QUESTIONNAIRE TO ASSESS QUALITY OF CARE IN DUTCH DIALYSIS CENTERS
PERCEIVED RISK,VALUE AND QUALITY OF LIFE FOR PATIENTS WITH OVERACTIVE BLADDER
DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME MEASURES IN URINARY INCONTINENCE
A NEW METHOD FOR TIME ADJUSTMENT OF THE NUMBER NEEDED TO TREAT REGARDING VARIABLE RELATIVE RISK REDUCTION
METHODOLOGICAL DESIGNS & OUTCOMES OF EFFECTIVENESS STUDIES—A LITERATURE REVIEW
INSTRUMENT STRENGTH AND PERFORMANCE OF A PARAMETRIC LATENT INDEX MODEL IN ESTIMATING AVERAGE TREATMENT EFFECT (ATE)
PERFORMANCE OF TWO CONDITIONAL EXPECTATION METHODS UNDER UNOBSERVED SELECTION BIAS
IMPROVING REPORTS OF PRO DATA TO SUPPORT AN EFFECTIVENESS CLAIM
ESTIMATING THE TRAJECTORY-ADJUSTED IMPACT OF ACUTE EVENTS ON PATIENT-REPORTED OUTCOMES
THE CONGRUENCE OF SELF-REPORT WITH OTHER MEASURES OF MEDICATION ADHERENCE
PATIENT SAFETY RESEARCH
INTERNET-BASED PATIENT REGISTRIES IN COMMUNITY PRACTICE
EVALUATING RETROSPECTIVE STUDY POSTERS PRESENTED AT THE ISPOR 7TH ANNUAL CONFERENCE
BEST PRACTICES
PHARMACOEPIDEMIOLGY
OPTIMIZING CLINICAL EFFECTIVENESS THROUGH ACTUARIAL MODELING IN HOSPITALS
DEVELOPING A HEALTH ECONOMIC EVALUATION DATABASE IN JAPAN
DO DIFFERENCES AMONG COST-EFFECTIVENESS ANALYSIS GUIDELINE RECOMMENDATIONS AFFECT POLICY CONCLUSIONS?
FACILITATING USER INTERACTION WITH PHARMACOECONOMIC MODELS
ARE PUBLISHED COST-UTILITY ANALYSES IMPROVING?
ECONOMIC EVALUATION IN CLINIC TRIALS
COMMUNITY OR PATIENT PREFERENCES FOR COST-UTILITY ANALYSES
SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES OF MEDICAL TECHNOLOGY IN THAILAND
A RELIABLE AND ROBUST ALGORITHM TO DETERMINE IN-HOSPITAL LENGTH OF STAY AND READMISSIONS USING RAMQ
AN INVESTIGATION OF PATIENT HETEROGENEITY AND THE POTENTIAL FOR BIAS IN MODELLING STUDIES
IS MARKOV CHAIN/DECISION TREE APPROACH BETTER THAN COST FUNCTION APPROACH IN MODELING THE PHARMACEUTICAL COSTS FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER? AN EMPIRICAL STUDY BASED ON A LARGE CLAIM DATABASE
PROBABILISTIC SENSITIVITY ANALYSES
INCREASING PUBMED YIELD FOR PHARMACOECONOMIC RESEARCH USING ITERATIVE SEARCH STRATEGIES
ECONOMIC AND OUTCOMES RESEARCH IN THE REAL WORLD
DO PHARMACOECONOMIC FELLOWSHIP PROGRAMS PROVIDE THE SKILLS NECESSARY FOR TODAY'S WORK ENVIRONMENT?
ISPOR QUALITY OF LIFE SPECIAL INTEREST GROUP—TRANSLATION AND CULTURAL ADAPTATION
DATABASES AND INSTRUCTION MANUALS
AN IMPROVED MODEL TO CALCULATE UTILITY SCORES FROM SF-36 DATA
ASSESSING FUNCTIONAL STATUS IN CHILDREN
COMPARING SHORT FORM 6D, STANDARD GAMBLE, AND HEALTH UTILITIES INDEX MARK 2 AND MARK 3 UTILITY SCORES
RELATIONSHIP OF QUALITY OF LIFE DOMAINS TO PREFERENCE-BASED MEASURES OF QUALITY OF LIFE
COMPARISON OF SF-36 SUMMARY AND PREFERENCE-BASED UTILITY SCORES ACROSS GROUPS DIFFERING IN DISEASE SEVERITY
QUALITY OF LIFE DIFFERENCES IN OLDER ADULTS WITH VARIED COMORBID CONDITIONS
JUSTIFYING THE DEVELOPMENT OF A LAY PANEL TO PRODUCE UTILITIES FOR USE IN HEALTH TECHNOLOGY ASSESSMENTS (HTAS)
IMPACT OF SOCIODEMOGRAPHICS ON QUALITY OF LIFE DOMAINS
VALIDATION OF EQUATIONS USED TO PREDICT WARFARIN DOSING DECISIONS
TELEMONITORS REDUCE HOSPITAL AND ER ADMISSIONS FOR HOMEBOUND CONGESTIVE HEART FAILURE (CHF) PATIENTS
PREDICTORS OF ADHERENCE TO ANTIHYPERTENSIVES IN A MANAGED CARE POPULATION
THE EFFECT OF STATIN DOSE ON ATTAINMENT OF TARGET LDL-C LEVELS
CLINICAL EFFECTIVENESS OF AMLODIPINE ON SYSTOLIC BLOOD PRESSURE AS MONOTHERAPY AND IN COMBINATION
A REVIEW OF THE PHARMACOTHERAPEUTIC MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION
TREATMENT OF PRIMARY PULMONARY HYPERTENSION (PPH)
ESTIMATING POPULATION BLOOD PRESSURE CONTROL AMONG US HYPERTENSIVE PATIENTS
META-ANALYSIS OF STATINS IN THE LOWERING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL TO EUROPEAN ATHEROSCLEROSIS SOCIETY TARGET USING ROSUVASTATIN AS A COMMON COMPARATOR
DEFINING OUTCOMES IN STUDIES OF BLEEDING MORBIDITY ASSOCIATED WITH ANTICOAGULATION THERAPY
EFFECTIVENESS OF CLINICAL PATHWAYS FOR PATIENTS WITH HEART FAILURE
ACHIEVEMENT OF THE EUROPEAN ATHEROSCLEROSIS SOCIETY LDL-C TARGET BY HYPERCHOLESTEROLAEMIC PATIENTS RECEIVING ROSUVASTATIN COMPARED TO ATORVASTATIN, PRAVASTATIN OR SIMVASTATIN
ENOXAPARIN USE IN PATIENTS WITH MECHANICAL HEART VALVES REQUIRING BRIDGING THERAPY FOR SUBTHERAPEUTIC CHRONIC ORAL ANTICOAGULATION
RACIAL VARIATION IN THE UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONS
WITHDRAWN
SMOKING DEPENDENCY
RELATIONSHIP BETWEEN PATIENT BELIEFS ABOUT MEDICATION AND SELF-REPORTED MEDICATION ADHERENCE SIX MONTHS AFTER DISCHARGE FOR ACUTE CORONARY SYNDROMES
A CONFIRMATORY FACTOR ANALYSIS EVALUATION OF THE CORONARY HEART DISEASE RISK FACTORS OF METABOLIC SYNDROME AND THE EFFECTIVENESS OF THE CURRENT ATP III GUIDELINES FOR IDENTIFICATION
SMOKING CESSATION
DYSLIPIDEMIA PATTERNS AMONG HIGH RISK MEMBERS OF A MANAGED CARE ORGANIZATION
TREATMENT PATTERNS AMONG NEWLY DIAGNOSED CORONARY HEART DISEASE PATIENTS
DISEASE MANAGEMENT REDUCES HEALTHCARE DISPARITIES IN HEART FAILURE PATIENTS
A COST-BENEFIT MODEL FOR PERINDOPRIL IN SECONDARY STROKE PREVENTION
RATES OF HOSPITALIZATIONS FOLLOWING ATHEROTHROMBOTIC STROKE AND ASSOCIATED COSTS
AN INVESTIGATION OF THE CARE NEEDS AFTER ACUTE ISCHEMIC STROKE
RATES OF VENOUS THROMBOEMBOLISM AND ASSOCIATED INPATIENT HEALTHCARE RESOURCE USE AMONG PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY IN AN INTEGRATED DELIVERY SYSTEM
THE IMPACT OF ATHEROTHROMBOTIC EVENTS ON RESOURCE USE AND COST IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE
ECONOMIC OUTCOMES ASSOCIATED WITH CHOICE OF TREATMENT IN DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM
HEALTH SERVICE UTILIZATION, COSTS AND OUTCOMES OF PATIENTS WHO USED DIFFERENT TYPES OF CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION
ECONOMIC EVALUATION OF LOSARTAN COMPARED WITH ATENOLOL IN THE TREATMENT OF HYPERTENSION WITH LEFT VENTRICULAR HYPERTROPHY
ECONOMIC IMPACT OF UNCONTROLLED HYPERTENSION AMONG NSAID USERS
EXCESS COSTS FOR SINGLE AGENT MEDICATION TREATMENT OF HYPERTENSION
COST-EFFECTIVENESS ANALYSIS OF SIMVASTATIN AND LOVASTATIN/EXTENDED-RELEASE NIACIN TO ACHIEVE LDL AND HDL GOAL USING NHANES DATA
DETERMINANTS OF COST EFFECTIVENESS IN CLINICAL GUIDELINES FOR CARDIOVASCULAR PROPHYLAXIS WITH STATINS
COST EFFECTIVENESS ANALYSIS OF HMG-COA REDUCTASE INHIBITORS IN A MEDICAID POPULATION
COST-EFFECTIVENESS OF TREATING BY SIMVASTATIN 40 MG/DAY HIGH VASCULAR RISK PATIENTS
BASELINE PREDICTORS OF ONE-YEAR COSTS AFTER ACUTE MYOCARDIAL INFARCTION IN THE ELDERLY
A COST AND COST-EFFECTIVENESS (CE) ANALYSIS OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR TRANDOLAPRIL IN THE TREATMENT OF POST INFARCTION IN THE US
IMPACT OF ANEMIA ON HF HOSPITAL LENGTH OF STAY
COST-EFFECTIVENESS OF RAMIPRIL IN PREVENTING CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS
HOSPITAL COSTS AND CHARGES ATTRIBUTABLE TO THE DEVELOPMENT OF ARI/ARF AFTER CABG
COST EFFECTIVENESS STUDY OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR VS. CONVENTIONAL TREATMENT IN PREVENTING SUDDEN DEATH AMONG PATIENTS WITH HEART FAILURE
PREDICTING THE BURDEN OF CONGESTIVE HEART FAILURE (CHF) IN A MANAGED CARE SETTING
EVALUATION ON THE COST OF MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN A LOCAL PUBLIC HOSPITAL IN HONG KONG
HOSPITALIZATION EXPENDITURE OF ACUTE RHEUMATIC FEVER AND CHRONIC RHEUMATIC HEART DISEASE IN THE UNITED STATES
NEW SOFTWARE TO ESTIMATE COSTS AND CALCULATE THE RETURN ON INVESTMENT OF TOBACCO CONTROL PROGRAMS IN A MANAGED CARE SETTING
PREDICTING THE SAVINGS AND RETURN ON INVESTMENT OF TOBACCO CONTROL PROGRAMS IN A MANAGED CARE SETTING USING MEDISAVE SMOKING CESSATION
COMPARISON OF WEIGHT-RELATED QUALITY OF LIFE IMPACTS BY AGE AND GENDER
COMPARISON OF WEIGHT-RELATED SYMPTOMS AND QUALITY-OF-LIFE IMPACTS BY BODY MASS INDEX
DESCRIPTION AND PREDICTIVE MODELING OF PERCEIVED WORK PERFORMANCE IN AN ACUTE CORONARY SYNDROME POPULATION
PREDICTIVE MODELS OF HEALTH-RELATED QUALITY OF LIFE UTILIZING PATIENT REPORTED OUTCOMES DATA FROM A POPULATION WITH A HISTORY OF ACUTE CORONARY SYNDROME
WHICH STATIN? A MULTICRITERIA DECISION ANALYSIS
RELATION BETWEEN MEDICATION COMPLIANCE AND GLUCOSE CONTROL IN PATIENTS WITH TYPE 2 DIABETES
IMPROVEMENT OF HEMOGLOBIN AIC (HBAIC) TESTING AND ANALYSIS OF PARTICIPANT-REPORTED RESULTS IN CAREPATTERNS® FOR DIABETES PROGRAM
EFFICACY OF INSULIN GLARGINE IN PATIENTS WITH TYPE 1 AND 2 DIABETES
OBTAINING QUALITY REAL-WORLD TREATMENT DATA FOR ECONOMIC MODELS
MEDICATION COMPLIANCE IN TYPE 2 DIABETES SUBJECTS
FACTORS ASSOCIATED WITH HIGH-RISK DIABETIC PATIENTS IN THE CALIFORNIA MEDICAID POPULATIONS (MEDI-CAL)
DIABETES RELATED DRUG UTILIZATION AND EXPENDITURES IN MEDICARE BENEFICIARIES WITH AND WITHOUT SUPPLEMENTAL PRESCRIPTION DRUG INSURANCE
WITHDRAWN
IMPACT OF AGE, GENDER, AND OUT-OF-POCKET COSTS ON THE TIME TO DISCONTINUATION OF ORAL ANTI-DIABETIC AGENTS AMONG PATIENTS WITH TYPE 2 DIABETES
A METHODOLOGY TO IDENTIFY HIGH-RISK PATIENTS WITH DIABETES IN THE CALIFORNIA MEDICAID POPULATION (MEDI-CAL)
DETERMINATION OF ASSOCIATION BETWEEN DRUG COSTS AND MEDICAL COSTS IN PATIENTS WITH TYPE 1 DIABETES
A COMPARISON OF TWO METHODS FOR ESTIMATING HEALTH CARE COSTS OF DIABETES
USING LINEAR REGRESSION TO APPROXIMATE RESULTS OF DECISION ANALYSIS
RESOURCE UTILIZATION USING INNOLET VS. VIAL/SYRINGE FOR DAILY INSULIN INJECTION IN A SUBGROUP OF ELDERLY DIABETIC PATIENTS
COST-EFFECTIVENESS ANALYSIS OF GRAFTSKIN (APLIGRAF) AND BECAPLERMIN (REGRANEX) IN DIABETIC NEUROPATHIC FOOT ULCERS
COST OF TYPE 2 DIABETES CARE IN AUSTRALIA—THE DIABCOST STUDY
ECONOMIC ANALYSIS OF THE USE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN PATIENTS WITH DIABETES MELLITUS
ESTIMATING THE COST-EFFECTIVENESS OF REPAGLINIDE PLUS METFORMIN VS. NATEGLINIDE PLUS METFORMIN OVER A 30-YEAR PERIOD
THE COST-EFFECTIVENESS OF TARKA FOR PREVENTING RENAL FAILURE IN TYPE 2 DIABETIC PATIENTS WITH HYPERTENSION IN THE US HEALTH CARE SETTING
SIMULATING THE LONG TERM COST-EFFECTIVENESS OF A COMBINATION REGIMEN OF REPAGLINIDE PLUS ROSIGLITAZONE VS. ROSIGLITAZONE MONOTHERAPY OVER A 30-YEAR PERIOD
COMPARISON OF HEALTHCARE COSTS FOR REPAGLINIDE, METFORMIN, REPAGLINIDE/METFORMIN, AND GLYBURIDE/METFORMIN WITHIN A MANAGED CARE ORGANIZATION
THE DIRECT COST OF DIABETES TYPE 2 IN POLAND—PRELIMINARY DATA FROM CODIP STUDY
INVESTIGATOR AND SITE CHARACTERISTICS OF THE NAVIGATOR TRIAL
FACTORS INFLUENCING THE DIAGNOSTIC TESTS PRESCRIBING FOR TYPE 2 DIABETES IN AMBULATORY PATIENTS
COST ANALYSIS OF DIABETES TREATMENT WITH GLARGINE INSULIN OR NPH INSULIN IN SPAIN
EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH NEUROPATHY USING THE NORFOLK QUALITY OF LIFE (QOL) TOOL
RISKING HEALTH TO AVOIDING INJECTIONS—STATED PREFERENCES OF TYPE 2 DIABETICS IN THE US AND CANADA
DEVELOPMENT OF AN INSTRUMENT TO MEASURE PATIENT EXPECTATION AND PREFERENCE FOR THE INSULIN INJECTION PEN
COST-EFFECTIVENESS OF RECOMBINANT HUMAN ERYTHROPOIETIN FOR PREVENTING TRANSFUSIONS IN CRITICALLY ILL PATIENTS
COST ANALYSIS OF PROPHYLACTIC TREATMENT OF CHILDREN WITH SEVERE HEMOPHILIA A IN CANADA
COST-EFFECTIVENESS OF TRANSFUSING PLATELET COMPONENTS PREPARED WITH PATHOGEN INACTIVATION TREATMENT IN ORTHOPEDIC SURGERY IN THE UNITED STATES
THE ECONOMIC IMPACT OF NOVOSEVEN® IN STEM CELL TRANSPLANTATION IN GERMANY AND THE UNITED STATES
LONG TERM COST OF ILLNESS STUDY FOR SEVERE HEMOPHILIC CHILDREN IN TORONTO
HEMOPHILIA ECONOMIC MODEL OF OUTCOMES
IMPROVEMENT IN QUALITY OF LIFE AND HEALTHCARE UTILISATION DURING GROWTH HORMONE REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS
DEVELOPMENT OF THE GROWTH HORMONE INJECTION QUESTIONNAIRE (GHIQ) FOR ADOLESCENTS
HEALTHCARE CONSUMPTION, QOL, AND PATIENT-REPORTED OUTCOMES DURING GH REPLACEMENT IN HYPOPITUITARY ADULTS
QUALITY ASSESSMENT OF META-ANALYSES OF RCTS OF PHARMACOTHERAPY IN MAJOR DEPRESSIVE DISORDER
A META-ANALYSIS AND COMMON COMPARATOR ANALYSIS OF OLANZAPINE VERSUS ZIPRASIDONE AND ARIPIPRAZOLE
THE TREATMENT CHARACTERISTICS AND OUTCOMES OF PERSONS WITH DEPRESSION AND ALCOHOLISM
ANALYSIS OF HEALTHCARE UTILIZATION PATTERNS AND ADHERENCE IN PATIENTS RECEIVING ANTIPSYCHOTIC MEDICATIONS
THE IMPACT OF MIRTAZAPINE COMPARED TO NON-TCA ANTIDEPRESSANTS ON WEIGHT CHANGE IN NURSING FACILITY RESIDENTS
EVALUATING THE EFFECTIVENESS OF FLUOXETINE 90 MG ADMINISTERED EVERY WEEK AND EVERY 2 WEEKS IN NURSING HOME RESIDENTS
A MARKOV COHORT SIMULATION ESTIMATING THE RISK OF DEVELOPING CORONARY HEART DISEASE IN PATIENTS USING ANTIPSYCHOTIC DRUGS
PHARMACOLOGIC TREATMENT OF HOSPITALIZED PATIENTS WITH BIPOLAR DISORDER
INFLUENCE OF PHYSICIAN MIX AND SUPPLY ON THE DIFFUSION OF ATYPICAL ANTIPSYCHOTIC AGENTS
ETHNICITY AND SCHIZOPHRENIA MEDICATION CHOICE
DOES THE SHORT-TERM ADMINISTRATION OF A BENZODIAZEPINE IMPROVE COMPLIANCE WITH ANTIDEPRESSANT THERAPY?
ASSESSING THE RELATIONSHIP OF GENERALIZED ANXIETY DISORDER AND PEPTIC ULCER DISEASE
POLYPHARMACOTHERAPY OF INPATIENTS WITH SCHIZOPHRENIA
CLINICAL PROFILES OF SSRI USERS
PREDICTORS OF DURATION OF VISITS AMONG PATIENTS DIAGNOSED WITH DEPRESSION IN THE AMBULATORY MEDICAL CARE SETTINGS
PREVALENCE AND TRENDS IN ANTIPSYCHOTIC POLYPHARMACY AMONG MEDICAID ELIGIBLE SCHIZOPHRENIA PATIENTS IN CALIFORNIA AND GEORGIA, 1998–2000
USE OF SEDATIVE/HYPNOTIC AGENTS BY AN ELDERLY AMBULATORY POPULATION
RETROSPECTIVE DRUG USE EVALUATION OF ANTIPSYCHOTIC AGENTS IN THE VETERANS ADMINISTRATION SYSTEM
DIFFERENCES AMONG ANTIPSYCHOTICS IN THE TIME TO ALL-CAUSE DRUG DISCONTINUATION
IMPACT OF A CONVERSION PROGRAM FROM SERTRALINE TO GENERIC FLUOXETINE IN A STAFF-MODEL MANAGED CARE ORGANIZATION ENHANCED BY PHYSICIAN PROFILING AND ACADEMIC DETAILING
REINFORCE AND ADVOCATE COMMUNITY AND SCHOOL EDUCATIONAL PROGRAM IN SAFETY USE OF MEDICATION AND PREVENTION OF DRUG ABUSE IN CENTRAL OF TAIWAN
A NATIONAL ESTIMATE OF INDIRECT COSTS ASSOCIATED WITH ANXIETY DISORDERS
PHARMACOECONOMIC COMPARISON BETWEEN TWO DRUG STRATEGIES OF TREATMENT OF ANXIETY DISORDERS
COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS PLACEBO IN RELAPSE PREVENTION IN PATIENTS WITH SOCIAL ANXIETY DISORDER
SOCIAL ANXIETY DISORDER
COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN ACUTE BIPOLAR MANIA
EFFECTS OF PATIENTS WITH BIPOLAR, SCHIZOPHRENIC, AND MAJOR DEPRESSIVE DISORDERS ON THE MENTAL AND OTHER HEALTHCARE EXPENSES OF FAMILY MEMBERS
THE IMPACT OF UNRECOGNIZED BIPOLAR DISORDERS FOR PATIENTS TREATED WITH ANTIDEPRESSANT MEDICATIONS
ECONOMIC BURDEN OF NOT RECOGNIZING BIPOLAR DISORDER PATIENTS
A COMPARISON OF MENTAL HEALTH RESOURCES USED BY PATIENTS WITH BIPOLAR DISORDER TREATED WITH RISPERIDONE, OLANZAPINE, OR QUETIAPINE
PATTERNS OF TREATMENT AMONG BIPOLAR DISORDER PATIENTS TREATED WITH ANTIDEPRESSANTS
AN ECONOMIC COMPARISON OF ANTIPSYCHOTICS IN TREATMENT OF SCHIZOPHRENIA
OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
COMPARISON OF OLANZAPINE VERSUS QUETIAPINE IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH SCHIZOPHRENIA
ATYPICAL ANTIPSYCHOTICS
ECONOMIC EVALUATION OF ATYPICAL ANTIPSYCHOTICS WITHIN THE WISCONSIN MEDICAID PROGRAM
THE ECONOMIC BURDEN OF DEPRESSION IN 2000
A STUDY OF THE ECONOMIC BURDEN OF DEPRESSION
DEPRESSION AND FIBROMYALGIA
EVALUATING THE COST-EFFECTIVENESS OF ST. JOHN'S WORT VERSUS FLUOXETINE FOR THE TREATMENT OF MILD TO MODERATE DEPRESSION
IMPACT OF DEPENDENTS' DEPRESSION ON EMPLOYEE HEALTH BENEFITS COST
TREATMENT OF DEPRESSION
THE COST-UTILITY OF BUPROPION SR VERSUS SERTRALINE IN THE TREATMENT OF LATE-LIFE DEPRESSION
UTILIZATION AND COST OF ATYPICAL ANTIPSYCHOTICS IN MEDICAID PATIENTS WITH DEPRESSION
COSTS AND EFFECTIVENESS OF METHADONE AND BUPRENORPHINE MAINTENANCE TREATMENTS IN WESTERN AUSTRALIA
COST CONSEQUENCES OF APPLYING APPROPRIATE USE EDITS TO SELECT HYPNOTIC AGENTS
VALIDATION OF ENGLISH AND CHINESE VERSIONS OF THE SQLS, SF-36 AND HUI3 IN PATIENTS WITH SCHIZOPHRENIA IN SINGAPORE
SUBJECTIVE TOLERABILITY WITH ZIPRASIDONE VS HALOPERIDOL IN ACUTE SCHIZOPHRENIA
PERFORMANCE OF THE SF-12 AND RAND-12 PHYSICAL AND MENTAL HEALTH SUMMARY SCORES IN PEOPLE PRACTICING MEDITATION
COMORBID DIABETES AND SCHIZOPHRENIA
IMPACT OF COMORBID DIABETES ON FUNCTIONING IN SCHIZOPHRENIA
PATIENT-VALUED HEALTH STATE UTILITIES FOR BIPOLAR DISORDER
IMPACT OF WEIGHT GAIN ON HEALTH-RELATED QUALITY OF LIFE (HRQL) OF BIPOLAR PATIENTS
MENTAL HEALTH COMORBIDITY PREVALENCE, PATTERNS, AND IMPACT ON QUALITY OF LIFE AMONG GULF WAR VETERANS
DO HEALTH EXPERIENCES IN DEPRESSION CHANGE PATIENTS' VALUES?
QUALITY OF LIFE TRAJECTORIES AMONG MASSACHUSETTS ADULTS WITH SUBSTANCE USE DISORDERS
PSORIASIS, QUALITY OF LIFE AND DEPRESSIVE SYMPTOMATOLOGY
COLLEGE STUDENTS AND STRESS
THE IMPLEMENTATION OF NEW TREATMENT GUIDELINES IN ASTHMA BY HEALTH CARE PROVIDERS
DEVELOPMENT OF A PROSPECTIVE, NONRANDOMIZED PATIENT REGISTRY TO MEASURE REAL-WORLD CLINICAL, ECONOMIC, AND HUMANISTIC OUTCOMES
CLINICAL EFFECTIVENESS OF BUDESONIDE AND FORMOTEROL IN A SINGLE INHALER IN PATIENTS WITH ASTHMA—AN AUDIT IN UK GENERAL PRACTICE
THE EFFECT OF A LETTER-BASED EDUCATIONAL PROGRAM FOR PRESCRIBERS AND PHARMACISTS ON ADHERENCE TO NATIONAL ASTHMA GUIDELINES AND HEALTHCARE UTILIZATION
COMPLIANCE WITH ASTHMA CONTROLLER MEDICATIONS
COMPARISON OF RISK FOR HOSPITAL AND/OR EMERGENCY DEPARTMENT VISITS FOR MEDICAID PATIENTS WITH COPD
USE OF LONG-TERM ASTHMA CONTROLLER MEDICATIONS BEFORE AND AFTER A HOSPITALIZATION OR EMERGENCY DEPARTMENT VISIT
COMPARISON OF THE ECONOMIC IMPACT OF MONTELUKAST AND INHALED CORTICOSTEROID AGENTS ON ALLERGIC RHINITIS-RELATED UTILIZATION IN PATIENTS WITH ASTHMA
THE NET COST OF ASTHMA TO NORTH CAROLINA (NC) MEDICAID AND IDENTIFICATION OF FACTORS DRIVING COSTS IN AN ASTHMATIC POPULATION
PREDICTING THE BENEFIT OF OPTIMIZING SEVERE ASTHMA MANAGEMENT IN A MANAGED CARE SETTING
CHANGES IN ASTHMA-RELATED HEALTHCARE UTILIZATION AND COSTS AFTER THE ADDITION OF SALMETEROL TO A MEDICAID POPULATION
BONE MINERAL DENSITY LOSS AFFECTS ESTIMATES OF THE COST-EFFECTIVENESS OF INHALED STEROIDS IN ASTHMA
ASSESSING THE COST IMPLICATIONS OF COMBINED PHARMACOTHERAPY IN THE LONG TERM MANAGEMENT OF ASTHMA
RATES OF ASTHMA-RELATED MEDICAL AND PRESCRIPTION RESOURCE UTILIZATION AND COSTS IN A MEDICAID POPULATION
RELATIONSHIP BETWEEN ADHERENCE RATE AND TOTAL MEDICAL AND DRUG COSTS
RESOURCE UTILIZATION (HOSPITAL AND PHYSICIAN COST/VISITS) AFTER INTRODUCTION OF THE NEW TREATMENT GUIDELINES IN ASTHMA (1997)
THE AVERAGE COSTS OF THE TREATMENT OF ASTHMA EXACERBATIONS IN IN-PATIENT CARE AND HOSPITAL EMERGENCY ROOM IN POLAND
PHARMACOECONOMIC COMPARISON BETWEEN TWO DRUG STRATEGIES OF TREATMENT OF RECURRENT ACUTE RHINOPHARYNGITIS IN 18-MONTH-OLD TO 4-YEAR-OLD CHILDREN
ASTHMA HEALTH CARE EXPENDITURE
IMPROVING PHARMACEUTICAL CARE BY THE PROCUREMENT OF PALIVIZUMAB THROUGH SPECIALTY DISTRIBUTION
THE ECONOMIC IMPACT OF HOMEOPATHIC MANAGEMENT
IS CISATRACURIUM COST EFFECTIVE FOR NEUROMUSCULAR BLOCKADE IN THE ICU? A MARKOV COMPUTER SIMULATION STUDY
ECONOMIC OUTCOMES OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH INHALED CORTICOSTEROIDS AND LONG-ACTING β-AGONISTS IN A HEALTH MAINTENANCE ORGANIZATION
ASSESSMENT OF THE IMPROVEMENTS IN QUALITY OF LIFE POST-LUNG TRANSPLANT
CULTURAL ADAPTATION AND VALIDATION OF CHILDHOOD ASTHMA QUESTIONNAIRE-C (CAQ-C) IN SINGAPORE
REVIEW OF QUALITY OF LIFE INSTRUMENTS IN PEDIATRIC ASTHMA
META-ANALYSIS OF THE EFFECTIVENESS OF MAMMOGRAPHY
A MULTIDIMENSIONAL ANALYSIS OF DELIVERY-CARE
COMPARISON OF DIRECT-TO-CONSUMER INTERVENTIONS BY A MEDICAID HEALTH PLAN TO INCREASE FOLIC ACID SUPPLEMENTATION IN WOMEN OF CHILDBEARING AGE
EVALUATION OF A PHARMACEUTICAL PATIENT ASSISTANCE PROGRAM
FEASIBILITY OF SIMPLIFYING COMPLEX DECISION TREES VIA LINEAR REGRESSION ANALYSIS
A COMPARISON OF RESOURCE UTILIZATION FROM INPATIENT VERSUS OUTPATIENT SURGERY
ECONOMIC BURDEN OF OSTEOPOROSIS, BREAST CANCER, AND CARDIOVASCULAR DISEASE AMONG WOMEN
THE LIFETIME MEDICAL COSTS OF WOMEN
ECONOMIC IMPACT OF SILDENAFIL CITRATE ON A PHARMACY BUDGET
COST OF ACCESS BY FORMULARY TYPE
COST IMPLICATION OF UNRESTRICTED ACCESS TO SILDENAFIL CITRATE IN FOUR EMPLOYER GROUP PRESCRIPTION PLANS
LONGITUDINAL DIFFERENCES IN PSYCHOLOGICAL ADJUSTMENT FOR MEN WITH ERECTILE DYSFUNCTION
PREDICTORS OF RESPONSE TO ERECTILE DYSFUNCTION TREATMENT AT 12 MONTHS
DEVELOPMENT OF A NEW QUALITY OF LIFE INSTRUMENT TO EVALUATE FEMALE SEXUAL DESIRE
BPH
BENIGN PROSTATIC HYPERPLASIA